China Medical System Holdings Ltd. engages in the production, marketing, promotion, and sale of drugs. The company employs 6,415 full-time employees The company went IPO on 2010-09-28. The firm's products include Plendil, Ursofalk, Augentropfen Stulln Mono Eye Drops, Hirudoid, Atopic Piel Series and Vmonalisa, among others. Its major marketed products cover the cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetic fields. The firm distributes its products within domestic market and to overseas markets.
根据最新的财务报表(Form-10K),China Medical System Holdings Limited 的总资产为 $0,净損失为 $0
CHSYF 的关键财务比率是什么?
China Medical System Holdings Limited 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
China Medical System Holdings Limited 的收入按细分市场或地理位置如何划分?
China Medical System Holdings Limited 最大收入來源為 Integrated Line,在最近的收益報告中收入為 7,750,902,245。就地區而言,China 是 China Medical System Holdings Limited 的主要市場,收入為 8,906,169,113。
China Medical System Holdings Limited 是否盈利?
無,根据最新的财务报表,China Medical System Holdings Limited 的净損失为 $0